Scientists have developed a new test that can help identify people who are likely to develop hepatocellular carcinoma. The approach uses a simple blood test to check for the patient's previous exposure to certain viruses.
Yale Cancer Center scientists have developed a cell screening method for agents that alter biologic functions. This approach uses thousands of artificial proteins called “traptamers” and may help to answer research questions that are difficult to address with other cell screening methods, including the SARS-CoV-2 virus, COVID-19.
A new American Cancer Society study puts a price tag on racial disparities in cancer mortality, finding that $3.2 billion in lost earnings would have been avoided in 2015 if non-Hispanic blacks had equal years of life lost from cancer deaths and earning rates as NH whites.
A phase III trial evaluating Keytruda monotherapy demonstrated a significant reduction in risk of disease progression in death in microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer.
The phase III ALEX study demonstrated an increased five-year survival rate with Alecensa (alectinib), compared with crizotinib, in people living with anaplastic lymphoma kinase-positive non-small cell lung cancer.
Xtandi plus androgen deprivation therapy reduced the risk of death in the phase III PROSPER trial evaluating Xtandi (enzalutamide) plus ADT versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer.
Computer scientists working with pathologists have trained an artificial intelligence tool to determine which patients with lung cancer have a higher risk of their disease coming back after treatment—part of Cancer Research UK's landmark TRACERx study.
In a study, an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status.
Researchers at Fox Chase Cancer Center found that breast cancer patients describe having thoughts and feelings that can prevent them from discussing cancer-related sexual issues with their healthcare providers, even if they would like to.
Two Immunoscore clinical studies in stage III colon cancer patients validated the clinical value of Immunoscore to refine patients stratification and predict which patients benefit most from 6 months adjuvant chemotherapy.
